Shilpa Biocare Pvt Ltd, a wholly owned subsidiary of Shilpa Medicare Limited, has entered into a strategic equity partnership with Gate2Brain, S.L. The agreement involves Shilpa becoming a strategic shareholder and the dedicated CMC, manufacturing, and regulatory partner for Gate2Brain's lead program, G2B-002. G2B-002 is a peptide-shuttle oncology asset designed to transport therapeutics across the blood-brain barrier for the treatment of central nervous system diseases. It has received Orphan Drug Designation from both the U.S. FDA and the EMA for its potential in treating diffuse intrinsic pontine glioma (DIPG) and pediatric glioblastoma (pGBM). The partnership allows Shilpa to contribute manufacturing and regulatory expertise to advance G2B-002 towards first-in-human studies, anticipated by FY28. The preclinical studies of the MiniAp4 peptide shuttle have shown promising results in drug transport to the brain. This marks Shilpa's fourth strategic equity partnership, aligning with its strategy to invest in differentiated innovation. The total contribution from Shilpa Medicare amounts to Euro 7 million (approximately ₹63 crore), securing a 30.4% equity stake in Gate2Brain. This includes a cash infusion of Euro 0.5 million, Euro 5.5 million for equity services, and Euro 1 million for project development.
